Disc Medicine, Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing therapies for hematologic diseases, with a focus on disorders of heme biology and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias and DISC-3405 for polycythemia vera and other blood disorders, supported by licensed antibody programs and outsourced manufacturing.

21.94

21.94

— Disc Medicine, Inc.
%
Clinical-stage drug candidates70% Small-molecule and biologic programs in development for rare and hematologic diseases.
Licensed antibody programs20% In-licensed antibody assets from AbbVie and Mabwell that expand the pipeline.
Development and manufacturing services10% Internal and outsourced activities to advance candidates through trials and scale-up.

Disc Medicine does not currently sell commercial products; its near-term counterparties are clinical investigators,...

  • Clinical development partnersprimary

    CROs, investigators, and CDMOs that support discovery, manufacturing, and trials.

  • Specialty hematology prescribersprimary

    Hematologists who would prescribe approved therapies for porphyrias, PV, and iron disorders.

  • Patients with rare hematologic diseasesprimary

    Patients with EPs, PV, and related disorders who need targeted, specialty treatments.

  • Payers and reimbursement decision makerssecondary

    Public and private payors that would determine coverage and access after approval.

  • Licensing and collaboration counterpartiessecondary

    Companies such as AbbVie and Mabwell that provide or may monetize pipeline rights.

Disc Medicine is headquartered in the United States and its development, regulatory, and financing activities are...

  • •United States is the operating and regulatory center
  • •Clinical development and financing are primarily U.S.-based
  • •Future commercialization is intended for major markets
  • •Foreign and foreign-owned vendors support some trial materials and services
  • •Supply-chain exposure matters because manufacturing is outsourced

Disc Medicine is focused on advancing a small number of differentiated hematology assets through clinical...

01
Advance lead clinical programsshort-term

Clinical data are the main value driver for a pre-revenue biotech and determine future approval odds.

02
Broaden the hematology pipelinemedium-term

Multiple shots on goal reduce single-asset risk and extend the platform beyond one disease area.

03
Secure manufacturing and supply resilienceshort-term

Clinical and future commercial supply depend on reliable CDMO execution and qualified backup capacity.

04
Preserve capital runwayshort-term

The company has no product revenue and must fund long development timelines before commercialization.

Disc Medicine faces the classic risks of a pre-commercial biotech: clinical failure, regulatory delay, and the...

critical

Clinical development failure

The pipeline is still in early clinical stages, so negative efficacy or safety data could eliminate value.

Scope
bitopertin, DISC-3405, and other pipeline assets
Materiality
high
high

Competitive displacement

Larger biotech and pharma companies are developing therapies for the same hematologic diseases.

Scope
EPs, anemia, and other rare hematology markets
Materiality
high
high

Manufacturing and CDMO concentration

The company relies on single-source third-party manufacturers for clinical supply.

Scope
drug substance and finished drug product supply
Materiality
high
high

Capital requirements and dilution

With no product revenue, operations depend on external financing to fund trials and overhead.

Scope
equity raises, debt, collaborations
Materiality
high
medium

Reimbursement and market access

Even approved rare-disease drugs can face limited coverage and slow uptake.

Scope
future commercial products
Materiality
medium
Research and development accruals
Operating loss and quarterly comparability
Stock-based compensation
GAAP operating expenses and net loss
Contingent license milestones and royalties
Potential future cash outflows and expense recognition
Going-concern style liquidity assessment
Cash runway disclosures and financing assumptions

BRISTOL MYERS SQUIBB CO

BMY · Pharmaceutical Preparations

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

Black Diamond Therapeutics, Inc.

BDTX · Biological Products, (No Diagnostic Substances)

Krystal Biotech, Inc.

KRYS · Biological Products, (No Diagnostic Substances)

Stoke Therapeutics, Inc.

STOK · Pharmaceutical Preparations

ROCKET PHARMACEUTICALS, INC.

RCKT · Pharmaceutical Preparations

: 28/04/2026